From Medicineworld.org: Bevacizumab (Avastin) for Treatment of cancer
Bevacizumab (Avastin) for Treatment of cancer
Bevacizumab (Avastin) was the first anti-angiogenic drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer. Anti-angiogenic drugs act by inhibiting the new blood vessel formation in the growing tumor. Bevacizumab (Avastin) is manufactured by Genentech, South San Francisco, Calif.
Preliminary results from a large, randomized clinical trial for patients with advanced colorectal cancer who had previously received treatment were released in November 2004
(http://www.nci.nih.gov/newscenter/pressreleases/BevacizumabOxaliplatin). This trial is different from the Genentech trial in February 2004 in several respects, particularly because it offered a different choice of chemotherapy. Researchers in this trial (known as E3200) found that the patients who received bevacizumab in combination with FOLFOX4 (a regimen of oxaliplatin, 5-fluorouracil and leucovorin) had a median overall survival of 12.5 months compared to patients treated with FOLFOX4 alone, who had a median overall survival of 10.7 months. This difference is statistically significant and corresponds to a 17 percent improvement in median overall survival. There was a 26 percent reduction in the risk of death for patients in this study who received bevacizumab plus FOLFOX4 compared to those who received FOLFOX4 alone.
A breast cancer clinical trial, which released initial results in April 2005
(http://www.nci.nih.gov/newscenter/pressreleases/AvastinBreast), demonstrated that bevacizumab, in combination with standard chemotherapy, delayed the progression of disease by an average of approximately 5 months. From December 2001 to May 2004, this randomized study enrolled 722 women who had recurrent or metastatic breast cancer, or cancer that had spread to other organs, that had not been previously treated with chemotherapy. The women were treated with bevacizumab in combination with paclitaxel, or paclitaxel alone. Those women receiving combination therapy showed a delay in development of their breast cancer that was statistically significant. This was the first study to show the benefit of anti-angiogenic therapy for breast cancer and was a major advance in the treatment of patients with metastatic disease.
A lung cancer study, which released its preliminary results in March 2005 (http://www.nci.nih.gov/newscenter/pressreleases/AvastinLung), showed that those patients receiving a combination therapy of bevacizumab and chemotherapy were living longer than patients receiving only standard chemotherapy. The interim results of this study were made public because the primary endpoint of improving overall survival had been achieved. Patients receiving a regimen of chemotherapy (paclitaxel and carboplatin) and bevacizumab had a median overall survival of 12.5 months compared to the control group, receiving only paclitaxel and carboplatin, who survived an average of 10.2 months. The improved survival of 2.3 months was statistically significant. The results of this randomized study were noteworthy because they revealed the potential for improved survival rates with the addition of an anti-angiogeneic therapy. It should be noted, however, that these results apply only to patients in the study (those with advanced non-squamous, non-small cell lung cancer who had not previously received systemic chemotherapy) and that the most significant adverse event observed in this study was life-threatening or fatal bleeding, primarily from the lungs.
NCI, in collaboration with Genentech, is currently evaluating the potential use of bevacizumab in a number of different cancers. NCI is sponsoring more than 30 trials using this drug, including Phase III clinical trials in advanced or metastatic renal cell carcinoma, pancreatic cancer, and ovarian cancer. NCI also is conducting a Phase III trial evaluating the use of the drug for colorectal cancer patients who have undergone potentially curative surgery. For current information about ongoing clinical trials using bevacizumab, please go to http://www.cancer.gov/clinicaltrials.
There are number of major side effects associated with the use of Bevacizumab (Avastin) including bleeding, arterial clots (which could lead to stroke and heart attack), bowel perforation, wound healing difficulties, and hypertension.
Avastin and IFL in metastatic colon cancer
NEJM June 03, 2004, Bevacizumab plus Irinotecan Flurouracil, and Leucovorin form metastatic colorectal cancer. Authors: Hurwitz, Fehrenbacher, Novotny, Cartwright et al. Highlights from the study:
Did you know?
Bevacizumab (Avastin) was the first anti-angiogenic drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer. Anti-angiogenic drugs act by inhibiting the new blood vessel formation in the growing tumor. Bevacizumab (Avastin) is manufactured by Genentech
Medicineworld.org: Bevacizumab (Avastin) for Treatment of cancer
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.